R. Giddings

发表

Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection

A. Copas, R. Bruton, A. Hayward, 2022, Nature Aging.

Robust SARS-CoV-2-specific and heterologous immune responses after natural infection in elderly residents of Long-Term Care Facilities

A. Copas, R. Bruton, C. Fuller, 2021, medRxiv.

Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study

A. Copas, A. Hayward, M. Shrotri, 2022, The Lancet Healthy Longevity.

Duration of vaccine effectiveness against SARS-CoV2 infection, hospitalisation, and death in residents and staff of Long-Term Care Facilities (VIVALDI): a prospective cohort study, England, Dec 2020-Dec 2021

A. Copas, A. Hayward, M. Shrotri, 2022, medRxiv.

Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England

H. Whitaker, S. Ladhani, M. Zambon, 2021, The Lancet Healthy Longevity.

Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study

A. Copas, R. Bruton, A. Hayward, 2022, The Lancet Healthy Longevity.

Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England

A. Copas, C. Fuller, A. Hayward, 2021, The Lancet Healthy Longevity.

Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review

G. Medley, S. Torres-Rueda, F. Bozzani, 2022, PharmacoEconomics.

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

A. Copas, P. Moss, C. Fuller, 2021, The Lancet Infectious Diseases.

Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward

L. Ghazaryan, P. Godfrey-Faussett, S. Torres-Rueda, 2023, PharmacoEconomics.

Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021

A. Copas, C. Fuller, M. Shrotri, 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

SARS-CoV-2 anti-spike antibody levels following second dose of ChAdOx1 nCov-19 or BNT162b2 in residents of long-term care facilities in England (VIVALDI)

A. Copas, R. Bruton, A. Hayward, 2022, medRxiv.

Reduced Antibody and Cellular Immune Responses Following Dual COVID-19 Vaccination Within Infection-Naïve Residents of Long-Term Care Facilities

A. Copas, R. Bruton, A. Hayward, 2021, SSRN Electronic Journal.

Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models

G. Medley, S. Torres-Rueda, F. Bozzani, 2023, PharmacoEconomics.

Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibody in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study

A. Copas, A. Hayward, M. Shrotri, 2021, medRxiv.

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study)

A. Copas, C. Fuller, A. Hayward, 2021, medRxiv.